Business Context and Reporting Period
Company: Senseonics Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 12, 2017
Reporting Period: Single event date (September 12, 2017)
This filing reports a specific regulatory milestone rather than a standard financial reporting period. The Company is a Delaware corporation focused on continuous glucose monitoring systems.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a current report regarding a specific event and does not contain financial statements or performance metrics.
Material Changes
Regulatory Approval: On September 12, 2017, the Company received CE mark approval for its Eversense XL Continuous Glucose Monitoring System. This approval allows the Company to market the device in European Economic Area countries.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) announcing the CE mark approval. No specific financial guidance or forward-looking projections are included in the text of this report.
Risks and Contingencies: The filing includes a standard disclaimer stating that the information speaks only as of the date of the report. The Company disclaims any obligation to update the information in the future, except as required by applicable law.
Investor Verification Checklist
- Verify the specific scope of the CE mark approval for the Eversense XL system (e.g., specific indications or limitations).
- Review the full text of the press release (Exhibit 99.1) for details on commercialization plans in Europe.
- Check subsequent filings for financial impact or revenue recognition related to this approval.
- Confirm the Company's current cash position and runway, as this filing does not disclose liquidity status.